Navigation Links
Echo Therapeutics to Present at Prestigious Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference
Date:9/16/2010

FRANKLIN, Mass., Sept. 16 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick Mooney, M.D., Echo's Chairman and Chief Executive Officer, will present at the prestigious Accredited Members, Inc. (AMI) Fall 2010 Small Cap/Micro Cap Investment Conference. The conference is scheduled for September 20-22 at the Loew's Coronado Bay Resort and Spa in San Diego, CA. Echo's presentation is scheduled for 1:50 p.m. PT on September 21, 2010.

Dr. Mooney will discuss the Company's development progress. Echo Therapeutics recently announced the successful completion of a clinical study to evaluate the ability of Prelude to ablate the skin prior to the application of OTC 4% lidocaine cream for faster-acting local dermal anesthesia. In addition, Echo recently completed the initial product development work on its Prelude SkinPrep System and the Company is now focused on completing the final steps of its regulatory advance to commercialization and leveraging its key strategic partnerships to generate product-related revenue.

The Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference is expected to feature 19 private and public presenting companies. Presentations will be made to more than 400 expected attendees, each a verified accredited investor. In addition, Echo Therapeutics will be featured on the AMI website at http://www.accreditedmembers.com, for one year.

About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

Jeffrey Stanlis

Media: Richard SternChairman and Chief Executive Officer

Partner, Hayden IR

Stern & Co.(508) 530-0329

(602) 476-1821

(212) 888-0044
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
2. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
3. Halozyme Therapeutics Announces Public Offering of Common Stock
4. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
5. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
6. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
7. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
8. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream
10. BioMarin Acquires ZyStor Therapeutics, Inc.
11. Nile Therapeutics Reports 2010 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
(Date:8/1/2017)... Aug. 1, 2017   CerSci Therapeutics , a ... Texas , has received notice from the National ... of Health (NIH) that it has been awarded a ... over $650,000 in 2017 with an additional $1,000,000 to ... New Drug application of their lead non-opioid drug candidate ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... devices. Through an educational webinar, they will present the line of epMotion automated ... learn how easy you can automate everyday pipetting tasks. , Ideal for scientists ...
(Date:8/18/2017)... Woodlands, TX (PRWEB) , ... August 18, 2017 ... ... protection assistance and financial planning services to communities in east Texas, is launching ... Pediatric Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body ... with its product now available through Jet.com. , After 25 years of development, ... drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re ...
Breaking Medicine News(10 mins):